Press Releases

<< Back
Sep 14, 2004

ZIOPHARM Forms Medical Advisory Board

ZIOPHARM Forms Medical Advisory Board

NEW HAVEN, CT SEPT 14 - ZIOPHARM Forms Medical Advisory Board

NEW HAVEN, CT SEPT 14 - Privately held ZIOPHARM, Inc., a developer of cancer drugs, announced the formation of its Medical Advisory Board.

The board's nine members are cancer experts and distinguished physician scientists from diverse specialties and academic centers and include three past presidents of ASCO (the American Society of Clinical Oncology), a past president of the AACR (American Association of Cancer Research) and a member of the National Academy of Sciences.

Jonathan J. Lewis, MD, PhD, ZIOPHARM's executive chairman and chief executive officer, said: "We are deeply honored and humbled by the decisions of these extraordinarily accomplished physicians to join us and to advise ZIOPHARM's development of new cancer drugs."

The advisory board's members are:

James O. Armitage, MD, Chairman of Oncology, University of Nebraska, former president of ASCO. Dr. James O. Armitage has served as chair of Internal Medicine, dean of the College of Medicine at Nebraska and currently is the Joe Shapiro Professor of Medicine in the section of Oncology/Hematology. He is a graduate of the University of Nebraska Medical Center. Dr. Armitage developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. Dr. Armitage is board-certified in internal medicine, medical oncology, and hematology. He is a fellow of both the American and Royal Colleges of Physicians, a member of the National Cancer Advisory Board, and past president of ASCO.

Joseph Bertino, MD, Associate Director, Cancer Institute of New Jersey, former president of AACR and ASCO. Dr. Joseph R. Bertino is currently associate director of the New Jersey Cancer Center and clinical professor at Robert Wood Johnson. Previously, Dr. Bertino was chairman of the Program of Molecular Pharmacology and Therapeutics at Memorial Sloan-Kettering Cancer Center and professor of Medicine and Pharmacology at Cornell University Medical College. He spent many years at Yale University as a professor, as Chief of Oncology and Chemotherapy, and as the first director of the Yale Comprehensive Cancer Center. Dr. Bertino is past president of AACR and ASCO.

George Demetri, MD, Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School. Dr. George Demetri is currently the director, Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute. He led the clinical development and regulatory approval of Gleevec(R) for its indication for gastrointestinal stromal tumor (GIST). Dr. Demetri's laboratory and clinical research focus is on the translation and clinical development of additional molecular-targeted agents in solid tumors.

Lawrence Einhorn, MD, Distinguished Professor of Medicine, Indiana University, former president of ASCO. Dr. Lawrence Einhorn is Distinguished Professor of Medicine, Section of Hematology/Oncology, Indiana University Medical Center. He is a pioneer in combination chemotherapy, especially for testicular cancer, where his work represents one of the most striking advances in cancer therapy. Dr. Einhorn has received many awards, including the Kettering Prize in Cancer Research. He is associate editor for Medical and Pediatric Oncology, and for Investigational New Drugs. Dr. Einhorn is a member of the National Academy of Sciences and past president of ASCO.

Robert Peter Gale, MD, PhD, DSc (Hon.), Chief Scientific Officer & Head of Research, ZIOPHARM, Inc. As head of research for ZIOPHARM, Dr. Robert Peter Gale brings more than 30 years of experience in cancer research and clinical trial design and interpretation. He has published several hundred studies in basic and clinical sciences. Dr. Gale is highly regarded as a clinical trials scientist and innovator. He and his colleagues at the Weizmann Institute of Science helped identify the molecular abnormality responsible for CML that laid the basis for developing Gleevec? Dr. Gale served on the faculty of the UCLA School of Medicine in the Department of Medicine, Division of Hematology and Oncology, and is widely known for his leadership in Chernobyl and the Soviet Union after having been engaged there by Presidents Gorbachev and Reagan. Most recently, Dr. Gale was senior vice president for medical affairs for Antigenics, Inc.

Alan Houghton, MD, Chairman of Tumor Immunology, Memorial Sloan-Kettering Cancer Center. Dr. Houghton holds the Ludwig Chair in Clinical Investigation, and is chairman of Clinical Immunology, co-head of the Melanoma Disease Management Team, and head of the Laboratory of Tumor Immunology at Memorial Sloan-Kettering Cancer Center. He is also chairman of the National Cancer Center Networks Melanoma Committee and co-chairman of the Melanoma Study Group of the national cooperative clinical trials group. Studies in Dr. Houghton's laboratory have identified molecules and molecular targets on cancer cells that may be useful for therapy, many of which are currently being evaluated in clinical trials.

Alberto Pappo, MD, The Hospital for Sick Children, University of Toronto, Chair of Rare Cancer Section - Children's Oncology Group. Dr. Alberto Pappo is professor of Hematology/Oncology at the Hospital for Sick Children in Toronto. Dr. Pappo is world-renowned in the basic and clinical research of rare cancers, especially in the pediatric setting. He is the chairman of the Rare Tumors Committee of the Children's Oncology Group. In his role as committee chair, Dr. Pappo has been instrumental in orphan drug development and novel clinical trial designs for rare cancer populations.

David Spriggs, MD, Head of Solid Tumor Oncology, Memorial-Sloan Kettering Cancer Center. David Spriggs, MD, is currently head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center. He is the Winthrop Rockefeller Professor in Medical Oncology. Dr. Spriggs is an internationally known solid-tumor oncologist whose research focuses on the genetic regulation of drug resistance and new chemotherapy regimens. Dr. Spriggs is also a physician-investigator in charge of translational research, linking clinical and laboratory observations together to better understand cancer and improve cancer treatment.

Mark Thornton, MD, PhD, Chief Medical Officer & Head of Product Development, ZIOPHARM, Inc. Dr. Mark Thornton is head of product development at ZIOPHARM and brings over 15 years of experience at the US FDA and in the pharmaceutical industry. While at the FDA, Dr. Thornton led the review teams for Erbitux(R) and Pegasys(R) and evaluated hundreds of INDs for both CDER and CBER. In the pharmaceutical industry, Dr. Thornton completed multiple product applications to the FDA while director of research for Otsuka America and as director of clinical research and evaluation at both North American Vaccines and Univax Biologics. Dr. Thornton's unique educational background combines graduate degrees in biostatistics/epidemiology with pharmacology/toxicology and a degree in medicine.

About ZIOPHARM, Inc.

ZIOPHARM, Inc. is a privately held company founded in January 2004 to develop and commercialize a diverse, risk-sensitive portfolio of in-licensed cancer therapies. All products are focused on addressing unmet medical needs, with the potential for expedited approval and broad usage.

ZIOPHARM's first product, ZIO-101, is expected to enter Phase I human trials in 1Q 2005. The company anticipates licensing of ZIO-201 by 4Q 2004. ZIOPHARM is actively evaluating and negotiating for other product candidates and plans to in-license a third cancer therapy by 2Q 2005. Each product candidate undergoes a tightly managed evaluation process leveraging the company's management team's combined 100+ years of oncology experience in clinical development, regulatory strategy, business development and product commercialization. For more information, please visit